Vera Therapeutics, Inc.
NASDAQ:VERA
48.09 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| -1.862 | -0.846 | 0.176 | 0.251 | 0.509 |
| Gross Profit
| 1.862 | 0.846 | -0.176 | -0.251 | -0.509 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 78.225 | 68.993 | 22.484 | 45.206 | 7.29 |
| General & Administrative Expenses
| 23.787 | 21.91 | 11.918 | 4.039 | 4.41 |
| Selling & Marketing Expenses
| -2.224 | 0 | 0 | 0 | 0 |
| SG&A
| 23.787 | 21.91 | 11.918 | 4.039 | 4.41 |
| Other Expenses
| 0 | 1.848 | 1.794 | -1.076 | 0 |
| Operating Expenses
| 102.012 | 90.903 | 34.402 | 49.245 | 11.7 |
| Operating Income
| -102.012 | -90.903 | -34.402 | -52.241 | -11.961 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 6.023 | 1.848 | 1.794 | -1.171 | 0.108 |
| Income Before Tax
| -95.989 | -89.055 | -32.608 | -53.412 | -11.853 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| Net Income
| -95.99 | -89.056 | -32.609 | -53.413 | -11.854 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.25 | -3.35 | -1.53 | -14.4 | -3.46 |
| EPS Diluted
| -2.25 | -3.35 | -1.53 | -14.4 | -3.46 |
| EBITDA
| -106.098 | -90.903 | -34.402 | -49.999 | -11.032 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |